Abstract
Monocytes that migrate into tissues during inflammatory episodes and differentiate to macrophages were previously classified as classically (M1) or alternatively (M2) activated macrophages, based on their exposure to different fate-determining mediators. These macrophage subsets display distinct molecular markers and differential functions. At the same time, studies from recent years found that the encounter of apoptotic leukocytes with macrophages leads to the clearance of this cellular “debris” by the macrophages, while concomitantly reprogramming/immune-silencing the macrophages. While some of the features of M2 differentiation, such as arginase-1 (murine) and 15-lipoxygenases (human and murine) expression, were also displayed by macrophages following the engulfment of apoptotic cells, it was not clear whether apoptotic cells can be regarded as an M2-like differentiating signal. In this manuscript we review the recent information regarding the impact of apoptotic cells on macrophage phenotype changes in molecular terms. We will focus on recent evidence for the in vivo existence of distinct pro-resolving macrophages and the role of apoptotic cells, specialized lipid mediators, and glucocorticoids in their generation. Consequently, we will suggest that these pro-resolving CD11blow macrophages have metamorphed from M2-like macrophages, and modulated their protein profile to accommodate the changes in their function.
Introduction
Macrophages are highly plastic monocyte-derived cells that acquire different molecular and functional phenotypes following exposure to different bioactive molecules and environments. The early studies on the interactions of macrophages and lymphocytes in battling bacterial infections revealed the T helper type 1 (Th1) secreted cytokine IFNγ to be involved in the classical activation of macrophages (Nathan et al., ). However, seminal studies by the groups of Gordon and Mantovani have extensively characterized additional macrophage subtypes activated in alternative manners (reviewed in Mantovani et al., ; Martinez et al., ). Since the major polarizing cytokines initially found to be involved in classical and alternative activation were derived from Th1 (IFNγ) and Th2 (IL-4 and IL-13) lymphocytes these activated macrophages were named M1 and M2, respectively. Later studies revealed that in addition to IL-4, alternative activation can also be induced by immune complexes and glucocorticoids (Martinez et al., ), and accordingly the subdivision of alternatively activated macrophages to M2a–c was instilled. M1 macrophages are important inducers and effectors in the Th1 response. They are instrumental in immune responses against intracellular microbes and tumors (Mantovani et al., ). M2 macrophages are more heterogeneous, but generally play a role in Th2 responses, such as killing and encapsulation of extracellular parasites, resolving type 1 inflammation, and promoting tissue repair and remodeling. M2 macrophages are also playing a role in immune regulation and promote tumor progression (Mantovani et al., ; Martinez et al., ). M1 and M2 macrophages are not only distinct in function, but also express different receptors and enzymes required for their activities. M1 macrophages express high levels of inflammatory cytokines (IL-12, IL-23, TNFα, IL-1β, and IL-6) and chemokines (CXCL9, 10, and 11, CCL2, 3, 4, and 5, and CXCL2), as well as enzymes involved in the generation of reactive oxygen species (ROS) and nitric oxide (NO; Mantovani et al., ). M2 macrophages express lower levels of inflammatory mediators, but high levels of IL-10, scavenger, mannose, and galactose receptors. Importantly, in mice, M2 express the enzyme arginase-1 that intercepts the NO generation pathway [though inducible NO synthase (iNOS)] to generate ornithine and polyamines that are instrumental in tissue repair and fibrosis (Hesse et al., ). Hence, the expression of iNOS and arginase-1 are major markers deciphering M1 and M2 macrophages. Additional markers of M2, such as YM1 and FIZZ1, were later identified in mouse macrophages (Raes et al., , ).
Macrophages also undergo dramatic molecular and functional changes upon encounter, interaction with, and uptake of apoptotic cells (efferocytosis) during the resolution of inflammation. In this article we will highlight some of the similarities between M2 differentiation and transcriptional events activated by early efferocytosis. In addition, we will discuss recent results that support the notion that efferocytosis can eventually transform macrophages to another phenotype that is postulated to limit tissue repair/fibrosis and promote macrophage regulatory properties at remote sites. In this regard, it is important to note the early studies that indicated “non-phlogistic” activation of monocytes by the pro-resolving lipid mediators lipoxins. This bioactivity of lipoxins resulted in increased adhesion and migration of human monocytes (Maddox and Serhan, ; Maddox et al., , ) hence prompting the notion that resolution-driven monocyte/macrophage activation promotes tissue repair and wound healing.
Efferocytosis as an Alternative Mode of Macrophage Activation
The recognition, engulfment, and responsiveness to apoptotic cells are cardinal properties of resident and inflammatory macrophages and play a role in processes, such as tissue morphogenesis and homeostasis, embryonic development, hematopoiesis, immunity, and the resolution of inflammation (Savill et al., ; Erwig and Henson, ; Ravichandran and Lorenz, ). The recognition and uptake of apoptotic cells by macrophages through “eat me” signals (and the absence of “do not eat me” signals) expressed on their surface and their cognate receptors have been extensively studied and reviewed (Ravichandran, ). However, apoptotic cells also transduce signals to the engulfing macrophages that result in significant molecular and functional adjustments that address physiological needs consequent to the identified cell death. During the resolution of inflammation, macrophages engulf apoptotic cells and consequently, apoptotic cell recognition evokes distinct signaling events (Patel et al., ) that block the release of pro-inflammatory mediators from macrophages. This release is activated by bacterial moieties, and its blockage, which is termed immune-silencing (Voll et al., 1997; Fadok et al., ; Kim et al., ), is accompanied by the production of TGFβ and IL-10 (Byrne and Reen, ; Huynh et al., ; Mitchell et al., ), cytokines that can promote resolution and wound repair. The engulfment of apoptotic leukocytes by macrophages also leads to inhibition of iNOS expression and stimulates the expression of arginase-1 in the RAW 264 macrophage cell line (Freire-De-Lima et al., ) thereby preventing reactive NO production. In addition, the production of angiogenic growth factors (Golpon et al., ) by macrophages is consequent to the uptake of apoptotic cells. Elucidation of the signaling pathways activated by efferocytosis revealed significant roles for nuclear transcriptional regulators, such as peroxisome proliferator activated receptor (PPAR)-γ (Freire-De-Lima et al., ; Johann et al., ) and -δ (Mukundan et al., ) as well as the liver X receptor (LXR; A-Gonzalez et al., ) in promoting anti-inflammatory properties.
It is important to note that while macrophages engulf tissue-infiltrating apoptotic PMN during the resolution of inflammation, different experimental models used different sources of apoptotic cells, including Jurkat T cells, mouse thymocytes, or human peripheral blood neutrophils. All types of apoptotic cells express phosphatidylserine on the outer leaflet of their cytoplasmic membrane, and this is apparently the major signaling module used by these cells to communicate their mortal status with phagocytic cells (Ravichandran, ). Nevertheless, it is conceivable that other molecules (“eat me signals”) are expressed on apoptotic cells of different sources to give a more detailed “report” as to the consequences of their demise. Thus, the interpretation of the results obtained following incubations of macrophages with apoptotic cells of different sources should be evaluated carefully depending on the source of apoptotic cells used.
The prototypic Th2 cytokines IL-4, IL-13, and IL-10, as well as immune responses to parasites were found to promote many of the outcomes of efferocytosis in macrophages. These cytokines are well appreciated antagonists of the M1 response and macrophage pro-inflammatory properties (Martinez et al., ) while IL-4 and IL-13 can also promote fibrosis through TGFβ production (Fichtner-Feigl et al., ; Wynn, 2008). IL-13 was also found to promote vascular endothelial growth factor production during lung injury (Corne et al., ). Importantly, IL-4 and IL-13 also activate PPAR-γ (Huang et al., ; Berry et al., ) and PPAR-δ (Kang et al., ) to promote monocyte/macrophage alternative activation. LXR was recently found to synergize with IL-4 in the induction of arginase-1 expression and promotion of an M2 phenotype in regressive atherosclerotic lesions (Pourcet et al., ). Thus, efferocytosis induces phenotypic and molecular switches and activates signaling pathways in macrophages that resemble M2 polarization. Moreover, M2 polarization promotes efferocytosis through induction of different molecular modules, whereas M1 macrophages exert reduced uptake of apoptotic cells. Along these lines, recent studies also found that efferocytosis is a self-promoting process, and that M2 pathways play key roles in mediating this feature of macrophage function. These aspects of efferocytosis are covered by Korns et al. () in this research topic and will not be elaborated on here. Nevertheless, while macrophages are paradoxically involved in both the generation of fibrosis and its resolution (Wynn and Barron, 2010) and efferocytosis and M2 polarization generate a positive feedback loop during resolution of inflammation, it is much less clear what are the events and mediators that stop M2 differentiation and tissue repair/remodeling short of excessive, fibrotic outcomes. Such events and mediators are inevitably required to complete the resolution of inflammation and restore homeostasis rather than end every infection with a debilitating scar.
15-lipoxygenase and its products
A major enzymatic pathway that mediates key events in the resolution of inflammation involves the expression and activation of 12/15-lipoxygenase (LO) in mice and 15-LO-1 in humans. 15-LO expression and activity are upregulated by IL-4 and IL-13 in murine and human monocytes, macrophages, and peripheral blood mononuclear cells (Levy et al., ; Nassar et al., ; Heydeck et al., ; Huang et al., ; Ariel et al., ). This upregulation leads to the production of 15-LO products from eicosatetraenoic and docosahexaenoic acids (ETA and DHA, respectively), such as 15-hydroxyeicosatetraenoic acid (15-HETE), lipoxin (LX) A4 and B4 (5S,6S,15S-trihydroxy-7E,9E,11Z,13E-EPA, and 5S,14R,15S-trihydroxy-6E,8Z,10E,12E-EPA, respectively), 17S-hydroxy-DHA (17S-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-DHA), and protectin D1 (10R,17S-dihydroxy-4Z,7Z,11E,13E,15Z,19Z-DHA). Macrophage expression of 12/15-LO was found to promote the production of resolvin (Rv) D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-DHA) and maresin 1 (7,14-dihydroxy-4Z,8,10,12,16Z,19Z-DHA), in addition to LXA4 and PD1 (Merched et al., ; Serhan et al., ). The expression of 12/15-LO was also found to be upregulated in mouse macrophages following their incubation with apoptotic cells (Freire-De-Lima et al., ; Schif-Zuck et al., ) and resulted in the production of 15-HETE and LXA4 (Freire-De-Lima et al., ). Macrophages from chronic granulomatous disease (CGD) mice display impaired efferocytosis that could be repaired by IL-4 through the expression of 12/15-LO and activation of PPAR-γ (Fernandez-Boyanapalli et al., ). Hence, 15-LO-mediated signaling seems to be a major convergence point for efferocytosis and M2 polarization, and its down-stream signaling pathways could play a paramount role in deciphering whether macrophages will become pro-fibrotic or will finalize the resolution sequel to restore tissue homeostasis.
Along these reasoning, 12/15-LO products have been shown to be anti-inflammatory and to promote tissue repair, while playing an anti-fibrotic and immune-regulatory role (Serhan, ). The major bioactive 12/15-LO products could be produced from arachidonic acid to yield 15-HETE or lipoxins, or from DHA to generate protectin D (PD)1, resolvins of the D series, and the recently identified macrophage product maresin 1 (Serhan, ). While 15-HETE binds PPARγ to mediate its anti-inflammatory actions (Huang et al., ), LXA4, PD1, and resolvin D1 seem to act through binding to cell surface GPCRs (Serhan et al., ), as well as the aryl hydrocarbon receptor (that binds LXA4; Machado et al., ). All these 12/15-LO products induce a broad spectrum of anti-inflammatory actions on neutrophils and macrophages, as well as other cell types (Wittwer and Hersberger, 2007; Serhan et al., ). Lipoxins and PD1 are produced during epithelial injury in the cornea and mediate wound repair in addition to counteracting inflammation (Gronert et al., ). On the other hand, 12/15-LO products also induce unique pro-resolving properties of macrophages and promote regulatory pathways in lymphocytes. LXA4, PD1, RvD1, and PPARγ agonists were all found to promote efferocytosis and enhance PMN clearance during resolution (Godson et al., ; Schwab et al., ; Fernandez-Boyanapalli et al., ; Krishnamoorthy et al., ). In addition, PD1 and RvD1 were found to promote macrophage departure of resolving inflammation sites (Schwab et al., ; Schif-Zuck et al., ). LXA4 and PD1 inhibited inflammatory cytokine secretion from T lymphocytes (Ariel et al., , ) and enhanced CCR5 expression on apoptotic PMN to promote clearance of its pro-inflammatory ligands (Ariel et al., ). Moreover, LXA4 was recently found to play a role in the generation of myeloid-derived suppressor cells (Zhang et al., 2010). Of note, LXA4, PD1, and RvD1 are potent inhibitors of fibrosis in the lung and kidney (Duffield et al., ; Martins et al., ; Borgeson et al., ). Therefore, 15-LO products can be generated by macrophages following their interaction with apoptotic cells and/or polarization to the M2 phenotype. In turn, these products not only block inflammation but can also shift the macrophage healing balance from tissue repair/fibrosis to pro-resolution, anti-fibrotic, and regulatory functions. The exact mode of production and action for the different 15-LO products is probably dependent on substrate availability, concentration formed in the healing tissue and additional cues from the resolving environment. Nevertheless, they seem to act in concert to promote post-inflammation tissue healing and return to homeostasis.
CD11Blow Macrophages – A New Phenotype Generated Following Satiated-Efferocytosis
Recent reports have indicated the co-existence of various macrophage phenotypes in resolving peritoneal cavities (Bystrom et al., ; Schif-Zuck et al., ). Macrophages from resolving murine peritonitis expressed an alternatively activated phenotype albeit with increase expression of M1 markers, such as cyclooxygenase 2 (COX 2) and iNOS (Bystrom et al., ). Thus, these macrophages were termed resolution-phase macrophages (rMs) and were postulated to have a hybrid phenotype of classically and alternatively activated macrophages (Bystrom et al., ). A recent report from the same group has indicated that rMs could be divided to at least three distinct populations based on F4/80 and Ly-6C expression, with varying expression of additional pro-inflammatory and anti-inflammatory markers as well as CD11b (Stables et al., ). Along these lines, we have recently characterized F4/80+ macrophages from resolving peritoneal exudates into two distinct macrophage subtypes: CD11bhigh and CD11blow (Schif-Zuck et al., ). CD11bhigh macrophages were found to express low to intermediate levels of the M1 markers iNOS, COX 2, and matrix metalloproteinase (MMP)-9 and high levels of the M2 marker arginase-1. These cells also expressed very low levels of 12/15-LO. In addition, these macrophages secret medium levels of inflammatory cytokines and chemokines, as well as IL-10, in response to TLR ligands, are highly phagocytic, and do not migrate to lymphoid tissues. CD11blow macrophages express even lower levels of iNOS, COX 2, and MMP-9 than CD11bhigh ones, but they also do not express arginase-1. In addition, these macrophages secrete very low levels of inflammatory cytokines and chemokines, and IL-10, but higher amounts of TGFβ. Moreover, CD11blow macrophages, despite containing higher numbers of apoptotic PMN, are no longer phagocytic and are prone to emigrate to remote sites. Hence, CD11blow macrophages were termed “satiated” (Schif-Zuck et al., ). A seminal report from Ravichandran and colleagues (Park et al., ) has recently revealed that the mitochondrial membrane protein UCP2 controls satiation vs. continued clearance of apoptotic cells, and it would be interesting to examine its role in the generation of CD11blow macrophages. The integration of the results from Schif-Zuck et al., Bystrom et al., and Stables et al. suggests rM/CD11bhigh macrophages are a mixed macrophage population with dominant M2-like characteristics, and some low-grade M1 activity and that early efferocytosis promotes the conversion of the M1-like population to an M2-like phenotype (Fadok et al., ; Freire-De-Lima et al., ; Korns et al., ) as well as enhanced phagocytosis/efferocytosis. However, the CD11blow subset of macrophages, although converting from the CD11bhigh subset ex vivo and in vivo (following late, threshold-meeting, efferocytosis; Schif-Zuck et al., ), are not M2-like, but rather display a distinct phenotype with its own molecular and functional characteristic (Figure 1). Of interest, a similar series of macrophage phenotype switches was found to take place during muscle injury and repair. These switches were induced by the engulfment of muscle debris that promoted TGFβ production and muscle regeneration (Arnold et al., ; Perdiguero et al., ). Importantly, the macrophage phenotype switch was mediated by a signaling cascade involving MAPK (Perdiguero et al., ) an essential module in macrophage inflammatory signaling (Kim et al., ).
Figure 1
Macrophages are important in limiting inflammation, excessive tissue repair, and fibrosis (Wynn and Barron, 2010). They also act at remote sites, such as lymphoid organs and adipose tissue (Schwab et al., ; Mukundan et al., ; Odegaard et al., ; Titos et al., ) to regulate acquired immune responses and metabolism. Since CD11blow macrophages are distinct from either M1 or M2, do not express the pro-fibrotic enzyme arginase-1, stop phagocytosing foreign particles and can be found at lymphoid organs and adipose tissue (Schif-Zuck et al., ; Titos et al., ), we suggest these macrophages display a new phenotype, now termed resolution-promoting macrophages (Mres), which might be involved in anti-fibrotic, immune-regulatory, and metabolic processes, and hence is critical for the local and systemic termination of inflammatory episodes. The “decision-making” of macrophages on which phenotype will be expressed at a given time and setting is probably controlled by multiple variants in their milieu, including the number of apoptotic PMN they acquired and local concentrations of pro-resolving lipid mediators (from 15-LO and other pathways) and glucocorticoids (Schif-Zuck et al., ; Titos et al., ). Other macrophage-inactivating and resolution-promoting cytokines, growth factors and lipid mediators, such as IL-10, TGFβ, and PPARγ ligands are likely to also be important in regulating the fate of macrophages during the resolution of inflammation and the return of tissues to homeostasis.
Statements
Acknowledgments
This work was supported by grants from the Israel Science Foundation (number 534/09), the Nutricia Research Foundationl, and the Marc Rich Foundation (to Amiram Ariel) and the National Institute of Health (R01 GM38765 and P01 GM095467 to Charles N. Serhan). Amiram Ariel is a recipient of the young scientist award from Teva Pharmaceuticals Ltd.
Conflict of interest
Charles N. Serhan is an inventor on patents (resolvins) assigned to BWH and licensed to Resolvyx Pharmaceuticals. Charles N. Serhan is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. Charles N. Serhan’ interests were reviewed and are managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.
References
1
A-GonzalezN.BensingerS. J.HongC.BeceiroS.BradleyM. N.ZelcerN.DenizJ.RamirezC.DiazM.GallardoG.De GalarretaC. R.SalazarJ.LopezF.EdwardsP.ParksJ.AndujarM.TontonozP.CastrilloA. (2009). Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity31, 245–258.10.1016/j.immuni.2009.06.018
2
ArielA.ChiangN.AritaM.PetasisN. A.SerhanC. N. (2003). Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J. Immunol. 170, 6266–6272.
3
ArielA.FredmanG.SunY. P.KantarciA.Van DykeT. E.LusterA. D.SerhanC. N. (2006). Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7, 1209–1216.10.1038/ni1392
4
ArielA.LiP. L.WangW.TangW. X.FredmanG.HongS.GotlingerK. H.SerhanC. N. (2005). The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280, 43079–43086.10.1074/jbc.M509796200
5
ArnoldL.HenryA.PoronF.Baba-AmerY.Van RooijenN.PlonquetA.GherardiR. K.ChazaudB. (2007). Inflammatory monocytes recruited after skeletal muscle injury switch into anti inflammatory macrophages to support myogenesis. J. Exp. Med. 204, 1057–1069.10.1084/jem.20070075
6
BerryA.BalardP.CosteA.OlagnierD.LaganeC.AuthierH.Benoit-VicalF.LepertJ. C.SeguelaJ. P.MagnavalJ. F.ChambonP.MetzgerD.DesvergneB.WahliW.AuwerxJ.PipyB. (2007). IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur. J. Immunol. 37, 1642–1652.10.1002/eji.200636625
7
BorgesonE.DochertyN. G.MurphyM.RodgersK.RyanA.O’sullivanT. P.GuiryP. J.GoldschmedingR.HigginsD. F.GodsonC. (2011). Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB J. 25, 2967–2979.10.1096/fj.11-185017
8
ByrneA.ReenD. J. (2002). Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J. Immunol. 168, 1968–1977.
9
BystromJ.EvansI.NewsonJ.StablesM.ToorI.Van RooijenN.CrawfordM.Colville-NashP.FarrowS.GilroyD. W. (2008). Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood112, 4117–4127.10.1182/blood-2007-12-129767
10
CorneJ.ChuppG.LeeC. G.HomerR. J.ZhuZ.ChenQ.MaB.DuY.RouxF.McardleJ.WaxmanA. B.EliasJ. A. (2000). IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J. Clin. Invest. 106, 783–791.10.1172/JCI9674
11
DuffieldJ. S.HongS.VaidyaV. S.LuY.FredmanG.SerhanC. N.BonventreJ. V. (2006). Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902–5911.
12
ErwigL. P.HensonP. M. (2007). Immunological consequences of apoptotic cell phagocytosis. Am. J. Pathol. 171, 2–8.10.2353/ajpath.2007.070135
13
FadokV. A.BrattonD. L.KonowalA.FreedP. W.WestcottJ. Y.HensonP. M. (1998). Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101, 890–898.10.1172/JCI1112
14
Fernandez-BoyanapalliR. F.FraschS. C.McphillipsK.VandivierR. W.HarryB. L.RichesD. W.HensonP. M.BrattonD. L. (2009). Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood113, 2047–2055.10.1182/blood-2008-05-160564
15
Fichtner-FeiglS.StroberW.KawakamiK.PuriR. K.KitaniA. (2006). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12, 99–106.10.1038/nm1332
16
Freire-De-LimaC. G.XiaoY. Q.GardaiS. J.BrattonD. L.SchiemannW. P.HensonP. M. (2006). Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281, 38376–38384.10.1074/jbc.M605146200
17
GodsonC.MitchellS.HarveyK.PetasisN. A.HoggN.BradyH. R. (2000). Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663–1667.
18
GolponH. A.FadokV. A.Taraseviciene-StewartL.ScerbaviciusR.SauerC.WelteT.HensonP. M.VoelkelN. F. (2004). Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J. 18, 1716–1718.
19
GronertK.MaheshwariN.KhanN.HassanI. R.DunnM.Laniado SchwartzmanM. (2005). A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280, 15267–15278.10.1074/jbc.M410638200
20
HesseM.ModolellM.La FlammeA. C.SchitoM.FuentesJ. M.CheeverA. W.PearceE. J.WynnT. A. (2001). Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of l-arginine metabolism. J. Immunol. 167, 6533–6544.
21
HeydeckD.ThomasL.SchnurrK.TrebusF.ThierfelderW. E.IhleJ. N.KuhnH. (1998). Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood92, 2503–2510.
22
HuangJ. T.WelchJ. S.RicoteM.BinderC. J.WillsonT. M.KellyC.WitztumJ. L.FunkC. D.ConradD.GlassC. K. (1999). Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature400, 378–382.10.1038/22572
23
HuynhM. L.FadokV. A.HensonP. M. (2002). Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41–50.10.1172/JCI200211638
24
JohannA. M.Von KnethenA.LindemannD.BruneB. (2006). Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. Cell Death Differ. 13, 1533–1540.10.1038/sj.cdd.4401832
25
KangK.ReillyS. M.KarabacakV.GanglM. R.FitzgeraldK.HatanoB.LeeC. H. (2008). Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7, 485–495.10.1016/j.cmet.2008.04.002
26
KimC.SanoY.TodorovaK.CarlsonB. A.ArpaL.CeladaA.LawrenceT.OtsuK.BrissetteJ. L.ArthurJ. S.ParkJ. M. (2008). The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat. Immunol. 9, 1019–1027.10.1038/ni.1640
27
KimS.ElkonK. B.MaX. (2004). Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity21, 643–653.10.1016/j.immuni.2004.09.009
28
KornsD.FraschS. C.Fernandez-BoyanapalliR.HensonP. M.BrattonD. L. (2011). Modulation of macrophage efferocytosis in inflammation. Front. Immun. 2:57.10.3389/fimmu.2011.00057
29
KrishnamoorthyS.RecchiutiA.ChiangN.YacoubianS.LeeC. H.YangR.PetasisN. A.SerhanC. N. (2010). Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. U.S.A. 107, 1660–1665.10.1073/pnas.0907342107
30
LevyB. D.RomanoM.ChapmanH. A.ReillyJ. J.DrazenJ.SerhanC. N. (1993). Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 92, 1572–1579.10.1172/JCI116738
31
MachadoF. S.JohndrowJ. E.EsperL.DiasA.BaficaA.SerhanC. N.AlibertiJ. (2006). Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12, 330–334.10.1038/nm1355
32
MaddoxJ. F.ColganS. P.ClishC. B.PetasisN. A.FokinV. V.SerhanC. N. (1998). Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity. FASEB J. 12, 487–494.
33
MaddoxJ. F.HachichaM.TakanoT.PetasisN. A.FokinV. V.SerhanC. N. (1997). Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272, 6972–6978.10.1074/jbc.272.11.6972
34
MaddoxJ. F.SerhanC. N. (1996). Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183, 137–146.10.1084/jem.183.1.137
35
MantovaniA.SicaA.LocatiM. (2005). Macrophage polarization comes of age. Immunity23, 344–346.10.1016/j.immuni.2005.10.001
36
MantovaniA.SicaA.SozzaniS.AllavenaP.VecchiA.LocatiM. (2004). The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686.10.1016/j.it.2004.09.015
37
MartinezF. O.HelmingL.GordonS. (2009). Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451–483.10.1146/annurev.immunol.021908.132532
38
MartinezF. O.SicaA.MantovaniA.LocatiM. (2008). Macrophage activation and polarization. Front. Biosci. 13, 453–461.10.2741/2692
39
MartinsV.ValencaS. S.Farias-FilhoF. A.MolinaroR.SimoesR. L.FerreiraT. P.E SilvaP. M.HogaboamC. M.KunkelS. L.FierroI. M.CanettiC.BenjamimC. F. (2009). ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J. Immunol. 182, 5374–5381.10.4049/jimmunol.0802259
40
MerchedA. J.KoK.GotlingerK. H.SerhanC. N.ChanL. (2008). Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595–3606.10.1096/fj.08-112201
41
MitchellS.ThomasG.HarveyK.CottellD.RevilleK.BerlasconiG.PetasisN. A.ErwigL.ReesA. J.SavillJ.BradyH. R.GodsonC. (2002). Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13, 2497–2507.10.1097/01.ASN.0000032417.73640.72
42
MukundanL.OdegaardJ. I.MorelC. R.HerediaJ. E.MwangiJ. W.Ricardo-GonzalezR. R.GohY. P.EagleA. R.DunnS. E.AwakuniJ. U.NguyenK. D.SteinmanL.MichieS. A.ChawlaA. (2009). PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 15, 1266–1272.10.1038/nm.2048
43
NassarG. M.MorrowJ. D.RobertsL. N.LakkisF. G.BadrK. F. (1994). Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269, 27631–27634.
44
NathanC. F.MurrayH. W.WiebeM. E.RubinB. Y. (1983). Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158, 670–689.10.1084/jem.158.3.670
45
OdegaardJ. I.Ricardo-GonzalezR. R.GoforthM. H.MorelC. R.SubramanianV.MukundanL.Red EagleA.VatsD.BrombacherF.FerranteA. W.ChawlaA. (2007). Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature447, 1116–1120.10.1038/nature05894
46
ParkD.HanC. Z.ElliottM. R.KinchenJ. M.TrampontP. C.DasS.CollinsS.LysiakJ. J.HoehnK. L.RavichandranK. S. (2011). Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. Nature477, 220–224.10.1038/nature10340
47
PatelV. A.LongacreA.HsiaoK.FanH.MengF.MitchellJ. E.RauchJ.UckerD. S.LevineJ. S. (2006). Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells: implications for the delayed clearance model of autoimmunity. J. Biol. Chem. 281, 4663–4670.10.1074/jbc.M604162200
48
PerdigueroE.Sousa-VictorP.Ruiz-BonillaV.JardiM.CaellesC.SerranoA. L.Munoz-CanovesP. (2011). p38/MKP-1-regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J. Cell Biol. 195, 307–322.10.1083/jcb.201104053
49
PourcetB.FeigJ. E.VengrenyukY.HobbsA.Kepka-LenhartD.GarabedianM.MorrisS. M.Jr.FisherE. A.Pineda-TorraI. (2011). LXR{alpha} regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ. Res. 109, 492–501.10.1161/CIRCRESAHA.111.241810
50
RaesG.DE BaetselierP.NoelW.BeschinA.BrombacherF.Hassanzadeh GHG. (2002). Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J. Leukoc. Biol. 71, 597–602.
51
RaesG.Van Den BerghR.DE BaetselierP.GhassabehG. H.ScottonC.LocatiM.MantovaniA.SozzaniS. (2005). Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J. Immunol. 174, 6561; author reply 6561–6562.
52
RavichandranK. S. (2011). Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity35, 445–455.10.1016/j.immuni.2011.09.004
53
RavichandranK. S.LorenzU. (2007). Engulfment of apoptotic cells: signals for a good meal. Nat. Rev. Immunol. 7, 964–974.10.1038/nri2214
54
SavillJ.DransfieldI.GregoryC.HaslettC. (2002). A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965–975.10.1038/nri957
55
Schif-ZuckS.GrossN.AssiS.RostokerR.SerhanC. N.ArielA. (2011). Saturated-efferocytosis generates pro-resolving CD11b (low) macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366–379.10.1002/eji.201040801
56
SchwabJ. M.ChiangN.AritaM.SerhanC. N. (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature447, 869–874.10.1038/nature05877
57
SerhanC. N. (2010). Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?Am. J. Pathol. 177, 1576–1591.10.2353/ajpath.2010.100322
58
SerhanC. N.KrishnamoorthyS.RecchiutiA.ChiangN. (2011). Novel anti-inflammatory – pro-resolving mediators and their receptors. Curr. Top. Med. Chem. 11, 629–647.
59
SerhanC. N.YangR.MartinodK.KasugaK.PillaiP. S.PorterT. F.OhS. F.SpiteM. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15–23.10.1084/JEM2067OIA15
60
StablesM. J.ShahS.CamonE. B.LoveringR. C.NewsonJ.BystromJ.FarrowS.GilroyD. W. (2011). Transcriptomic analyses of murine resolution-phase macrophages. Blood118, e192–e208.10.1182/blood-2011-04-345330
61
TitosE.RiusB.Gonzalez-PerizA.Lopez-VicarioC.Moran-SalvadorE.Martinez-ClementeM.ArroyoV.ClariaJ. (2011). Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 187, 5408–5418.10.4049/jimmunol.1100225
62
VollR. E.HerrmannM.RothE. A.StachC.KaldenJ. R.GirkontaiteI. (1997). Immunosuppressive effects of apoptotic cells. Nature390, 350–351.10.1038/37022
63
WittwerJ.HersbergerM. (2007). The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids77, 67–77.10.1016/j.plefa.2007.08.001
64
WynnT. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210.10.1002/path.2277
65
WynnT. A.BarronL. (2010). Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30, 245–257.10.1055/s-0030-1255354
66
ZhangB.JiaH.LiuJ.YangZ.JiangT.TangK.LiD.HuangC.MaJ.ShenG. X.YeD.HuangB. (2010). Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. J. Immunol. 185, 7199–7206.10.4049/jimmunol.0903245
Summary
Keywords
resolution of inflammation, macrophage differentiation, efferocytosis, pro-resolving lipid mediators
Citation
Ariel A and Serhan CN (2012) New Lives Given by Cell Death: Macrophage Differentiation Following Their Encounter with Apoptotic Leukocytes during the Resolution of Inflammation. Front. Immun. 3:4. doi: 10.3389/fimmu.2012.00004
Received
29 August 2011
Accepted
07 January 2012
Published
31 January 2012
Volume
3 - 2012
Edited by
Jerrold S. Levine, University of Illinois at Chicago, USA
Reviewed by
Pablo Pelegrin, Hospital Universitario Virgen Arrixaca, Spain; Patrizia Rovere Querini, Vita-Salute University, Italy
Copyright
© 2012 Ariel and Serhan.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
*Correspondence: Amiram Ariel, Department of Biology, University of Haifa, Haifa 31905, Israel. e-mail: amiram@research.haifa.ac.il
This article was submitted to Frontiers in Inflammation, a specialty of Frontiers in Immunology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.